Cargando…

Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs

The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved an...

Descripción completa

Detalles Bibliográficos
Autores principales: Łukasiuk, Katarzyna, Lasoń, Władysław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917847/
https://www.ncbi.nlm.nih.gov/pubmed/36769250
http://dx.doi.org/10.3390/ijms24032928
_version_ 1784886466434826240
author Łukasiuk, Katarzyna
Lasoń, Władysław
author_facet Łukasiuk, Katarzyna
Lasoń, Władysław
author_sort Łukasiuk, Katarzyna
collection PubMed
description The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved animal models may accelerate designing antiepileptogenic and epilepsy-modifying drugs. Epileptogenesis triggers a vast array of genomic, epigenomic and transcriptomic changes, which ultimately lead to morphological and functional transformation of specific neuronal circuits resulting in the occurrence of spontaneous convulsive or nonconvulsive seizures. Recent decades unraveled molecular processes and biochemical signaling pathways involved in the proepileptic transformation of brain circuits including oxidative stress, apoptosis, neuroinflammatory and neurotrophic factors. The “omics” data derived from both human and animal epileptic tissues, as well as electrophysiological, imaging and neurochemical analysis identified a plethora of possible molecular targets for drugs, which could interfere with various stages of epileptogenetic cascade, including inflammatory processes and neuroplastic changes. In this narrative review, we briefly present contemporary views on the neurobiological background of epileptogenesis and discuss the advantages and disadvantages of some more promising molecular targets for antiepileptogenic pharmacotherapy.
format Online
Article
Text
id pubmed-9917847
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99178472023-02-11 Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs Łukasiuk, Katarzyna Lasoń, Władysław Int J Mol Sci Review The pharmacological treatment of epilepsy is purely symptomatic. Despite many decades of intensive research, causal treatment of this common neurologic disorder is still unavailable. Nevertheless, it is expected that advances in modern neuroscience and molecular biology tools, as well as improved animal models may accelerate designing antiepileptogenic and epilepsy-modifying drugs. Epileptogenesis triggers a vast array of genomic, epigenomic and transcriptomic changes, which ultimately lead to morphological and functional transformation of specific neuronal circuits resulting in the occurrence of spontaneous convulsive or nonconvulsive seizures. Recent decades unraveled molecular processes and biochemical signaling pathways involved in the proepileptic transformation of brain circuits including oxidative stress, apoptosis, neuroinflammatory and neurotrophic factors. The “omics” data derived from both human and animal epileptic tissues, as well as electrophysiological, imaging and neurochemical analysis identified a plethora of possible molecular targets for drugs, which could interfere with various stages of epileptogenetic cascade, including inflammatory processes and neuroplastic changes. In this narrative review, we briefly present contemporary views on the neurobiological background of epileptogenesis and discuss the advantages and disadvantages of some more promising molecular targets for antiepileptogenic pharmacotherapy. MDPI 2023-02-02 /pmc/articles/PMC9917847/ /pubmed/36769250 http://dx.doi.org/10.3390/ijms24032928 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Łukasiuk, Katarzyna
Lasoń, Władysław
Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title_full Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title_fullStr Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title_full_unstemmed Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title_short Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
title_sort emerging molecular targets for anti-epileptogenic and epilepsy modifying drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917847/
https://www.ncbi.nlm.nih.gov/pubmed/36769250
http://dx.doi.org/10.3390/ijms24032928
work_keys_str_mv AT łukasiukkatarzyna emergingmoleculartargetsforantiepileptogenicandepilepsymodifyingdrugs
AT lasonwładysław emergingmoleculartargetsforantiepileptogenicandepilepsymodifyingdrugs